MTOR inhibitors block kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis

Cancer Research

Volumn 73, Issue 7, 2013, Pages 2235-2246

  Roy, Debasmita ^a   Sin, Sang Hoon ^a,b   Lucas, Amy ^a,b   Venkataramanan, Raman ^c   Wang, Ling ^a,b   Eason, Anthony ^a,b   Chavakula, Veenadhari ^a,b   Hilton, Isaac B ^a   Tamburro, Kristen M ^a   Damania, Blossom ^a,b   Dittmer, Dirk P ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; CYCLOSPORIN A; DOXORUBICIN; EVEROLIMUS; GROWTH FACTOR; INTERLEUKIN 1BETA; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; RITONAVIR; TACROLIMUS; TEMSIROLIMUS; VASCULOTROPIN; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; IC 50; IMMUNOMODULATION; IN VIVO STUDY; KAPOSI SARCOMA; MONOTHERAPY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MODELS, ANIMAL; DNA, VIRAL; DOXORUBICIN; FLUORESCENT ANTIBODY TECHNIQUE; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; SARCOMA, KAPOSI; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875973051     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1851     Document Type: Article

References (63)

1. Jemal A, Bray F, Forman D, O'Brien M, Ferlay J, Center M, et al. Cancer burden in Africa and opportunities for prevention. Cancer 2012;118: 4372-84.
2. Ganem D. KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine. J Clin Invest 2010;120: 939-49.
3. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
4. Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010;116:3969-77.
5. Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 1999;96:4546-51.
6. Dittmer D, Lagunoff M, Renne R, Staskus K, Haase A, Ganem D. A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol 1998;72:8309-15.
7. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 1997;272:19625-31.
8. Wan X, Wang H, Nicholas J. Human herpesvirus 8 interleukin-6 (vIL-6) signals through gp130 but has structural and receptor-binding properties distinct from those of human IL-6. J Virol 1999;73:8268-78.
9. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997;385: 347-50.
10. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000;60: 4873-80.
11. Brinkmann MM, Schulz TF. Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. J Gen Virol 2006;87:1047-74.
12. Wang L, Dittmer DP, Tomlinson CC, Fakhari FD, Damania B. Immortalization of primary endothelial cells by the K1 protein of Kaposi's sarcoma-associated herpesvirus. Cancer Res 2006;66:3658-66.
13. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
14. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34.
15. Uddin S, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, Gutierrez MI, et al. Inhibition of phosphatidylinositol 3'-kinase/AKT signalingpromotes apoptosis ofprimary effusion lymphoma cells. Clin Cancer Res 2005;11:3102-8.
16. Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood 2010;115: 4455-63.
17. Sin SH, Roy D, Wang L, Staudt MR, Fakhari FD, Patel DD, et al. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood 2007;109: 2165-73.
18. Montaner S, Sodhi A, Pece S, Mesri EA, Gutkind JS. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res 2001;61:2641-8.
19. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-23.
20. Baker H, Sidorowicz A, Sehgal SN, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. J Antibiot (Tokyo) 1978;31:539-45.
21. Guenova E, Metzler G, Hoetzenecker W, Berneburg M, Rocken M. Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment. Arch Dermatol 2008;144:692-3.
22. Yaich S, Zagdane S, Charfeddine K, Hssairi D, Hachicha J. Simultaneous Hodgkin's disease and Kaposi sarcoma in a renal transplant recipient. Saudi J Kidney Dis Transpl 2010;21:306-9.
23. Ho CM, Huang SF, Hu RH, Ho MC, Wu YM, Lee PH. Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient. Clin Transpl 2010;24:127-32.
24. Boratynska M, Zmonarski SC, Klinger M. Reccurence of Kaposi's sarcoma after increased exposure to sirolimus. Int Immunopharmacol 2006;6:2018-22.
25. Babel N, Eibl N, Ulrich C, Bold G, Sefrin A, Hammer MH, et al. Development of Kaposi's sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transpl Infect Dis 2008;10:59-62.
26. Krown SE, Roy D, Lee JY, Dezube BJ, Reid EG, Venkataramanan R, et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium Study. J Acquir Immune Defic Syndr 2012;59:447-54.
27. Dittmer DP, Bhatt AP, Damania B. Rapalogs in viral cancers. Expert Opin Investig Drugs 2012;21:135-8.
28. Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ Jr, Miles D, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS ONE 2011;6:e23379.
29. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a doubleblind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-56.
30. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27: 3822-9.
31. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) 1987; 40:1256-65.
32. Fakhari FD, Jeong JH, Kanan Y, Dittmer DP. The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Investig 2006;116:735-42.
33. Roy D, Sin SH, Damania B, Dittmer DP. Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines. Blood 2011;118:e32-9.
34. Chen W, Hilton IB, Staudt MR, Burd CE, Dittmer DP. Distinct p53, p53: LANA, and LANA complexes in Kaposi's sarcoma-associated herpesvirus lymphomas. J Virol 2010;84:3898-908.
35. Staudt MR, Kanan Y, Jeong JH, Papin JF, Hines-Boykin R, Dittmer DP. The tumor microenvironment controls primary effusion lymphoma growth in vivo. Cancer Res 2004;64:4790-9.
36. Roy D, Dittmer DP. Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma. Am J Pathol 2011;179:2108-19.
37. Wang L, Damania B. Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res 2008;68: 4640-8.
38. Herndier BG, Werner A, Arnstein P, Abbey NW, Demartis F, Cohen RL, et al. Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals. AIDS 1994;8: 575-81.
39. Albini A, Paglieri I, Orengo G, Carlone S, Aluigi MG, DeMarchi R, et al. The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS 1997;11:713-21.
40. Sturzl M, Gaus D, Dirks WG, Ganem D, Jochmann R. The Kaposi's sarcoma-derived cell line SLK is not of endothelial origin, but is a contaminant from a known renal carcinoma cell line. Int J Cancer. 2012 Sep 17. [Epub ahead of print].
41. Flore O, Rafii S, Ely S, O'Leary JJ, Hyjek EM, Cesarman E. Transformation of primary human endothelial cells by Kaposi's sarcomaassociated herpesvirus. Nature 1998;394:588-92.
42. Lagunoff M, Bechtel J, Venetsanakos E, Roy AM, Abbey N, Herndier B, et al. De novo infection and serial transmission of Kaposi's sarcomaassociated herpesvirus in cultured endothelial cells. J Virol 2002;76: 2440-8.
43. Grundhoff A, Ganem D. Inefficient establishment of KSHV latency suggests an additional role for continued lytic replication in Kaposi sarcoma pathogenesis. J Clin Investig 2004;113:124-36.
44. An FQ, Folarin HM, Compitello N, Roth J, Gerson SL, McCrae KR, et al. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 2006;80:4833-46.
45. Kedes DH, Lagunoff M, Renne R, Ganem D. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. J Clin Investig 1997;100:2606-10.
46. Adang LA, Parsons CH, Kedes DH. Asynchronous progression through the lytic cascade and variations in intracellular viral loads revealed by high-throughput single-cell analysis of Kaposi's sarcomaassociated herpesvirus infection. J Virol 2006;80:10073-82.
47. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS J 2004;6:e28.
48. Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 2009;8:1026-9.
49. Sarek G, Kurki S, Enback J, Iotzova G, Haas J, Laakkonen P, et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Investig 2007;117:1019-28.
50. HaraK, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, WengQP, et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 1997;272:26457-63.
51. Samaniego F, Markham PD, Gendelman R, Watanabe Y, Kao V, Kowalski K, et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 1998;152:1433-43.
52. Sturzl M, Brandstetter H, Zietz C, Eisenburg B, Raivich G, Gearing DP, et al. Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi's sarcoma: a combined in vitro and in vivo analysis. Oncogene 1995;10:2007-16.
53. Cornali E, Zietz C, Benelli R, Weninger W, Masiello L, Breier G, et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 1996;149:1851-69.
54. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
55. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66:5549-54.
56. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci U S A 1997;94:979-84.
57. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000;156:361-81.
58. Ocque R, Tochigi N, Ohori NP, Dacic S. Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens. Am J Clin Pathol 2011;136:81-7.
59. D'Amico F, Fuxman C, Nachman F, Bitetti L, Fauda M, Echevarria C, et al. Visceral Kaposi's sarcoma remission after intestinal transplant. First case report and systematic literature review. Transplantation 2010;90:547-54.
60. Gutierrez-Dalmau A, Sanchez-Fructuoso A, Sanz-Guajardo A, Mazuecos A, Franco A, Rial MC, et al. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma. Transplant Proc 2005;37: 3836-8.
61. Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. Nat Genet 2004;36: 683-5.
62. Boshoff C, Schulz TF, Kennedy MM, Graham AK, Fisher C, Thomas A, et al. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1995;1:1274-8.
63. Brunn GJ, Fadden P, Haystead TA, Lawrence JC Jr. The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus. J Biol Chem 1997;272:32547-50.